Denali Therapeutics (DNLI) said Wednesday the US Food and Drug Administration has given breakthrough therapy designation for tividenofusp alfa to treat people with Hunter syndrome, a rare genetic disease.
The designation was created to quicken the development and review of candidate drugs to treat serious or life-threatening diseases, the company said.
The label is in addition to fast track designation, orphan drug designation, and rare pediatric disease designation that were all previously given by the FDA for tividenofusp alfa to treat Hunter syndrome, Denali added.
Denali said it plans to file a biologics license application for tividenofusp alfa early this year.
The company's shares were rising 1.6% in recent trading.
Price: 21.52, Change: +0.34, Percent Change: +1.61
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。